BPC-157 side effects: what small human studies can show
Human safety evidence for BPC-157 includes a two-person intravenous pilot published in 2025. Our September 2026 PubMed search found 49 records using a safety term, but publication tags do not capture every human study. The FDA's own entry says the agency lacks enough information to know whether the peptide would cause harm. Sellers read that as reassurance. It is the opposite of one.
What this comes down to
- The September 2026 search found no trial-tagged BPC-157 reports. A two-person uncontrolled safety pilot exists, but cannot measure a side-effect rate against placebo.
- Of the 228 records, 162 carry PubMed's animal indexing tag. The safety literature that exists is largely rat work.
- The FDA names specific serious adverse events for CJC-1295 and for ipamorelin on the same page. For BPC-157 it names none — because it has none, not because there are none.
- Two 2026 reviews in the orthopedic and sports medicine literature reach the same place: promising animal data, scarce human safety data, real potential for harm.
- All records228
- Tagged as animal work162 of 228
- Using a safety word49 of 228
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee considered whether BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon and Semax should be added to the 503A bulks list, the list that lets a state-licensed pharmacy compound a substance with no approved product. The FDA's own briefing document proposed that none of the seven be added[2]. Trade press reports that the committee disagreed for six of them: 8 to 6 with one abstention for BPC-157, KPV and TB-500 together, 7 to 5 for MOTS-c, and yes votes for epitalon and Semax, with emideltide voted down[3]. The vote is advisory. As of October 2026 the FDA and HHS have not added any of them to the list, so the legal position of BPC-157 described here has not changed.
What is actually in the file
BPC-157 has a large literature and very limited human safety data. Two hundred and twenty-eight records. A hundred and sixty-two of them carry PubMed's animal indexing tag. Forty-nine use a safety, adverse, toxicity or tolerability term somewhere in the title or abstract, and twenty of those are indexed as being about humans — which marks a paper as concerning people, not as having given anyone the drug. The September 2026 trial filter returned no records, but a two-person intravenous pilot published in 2025 assessed short-term safety without a placebo group[4]. The approval side of that story is its own article; this one is only about harm.[1]
The safety search, and the proof the filter works. A PubMed search finds 49 results; the same search for semaglutide finds 2,088.
Forty-nine papers mentioning safety reads like a body of evidence and isn't one. A rat study reporting that a dose was tolerated is a safety word in a database field. It tells you nothing about what happens when an adult injects a compounded version of the same molecule every day for a year, which is what is actually being sold.
The FDA cites limited safety information for BPC-157
The most useful thing on the FDA's compounding page isn't what it says about BPC-157. It's what it says about the peptides listed a few rows away. For CJC-1295 the agency names actual events[5].
“FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”
[5]
For ipamorelin it goes further and names a death. For BPC-157 the same agency, on the same page, in the same format, records that it has identified no or only limited safety information and therefore cannot say whether the drug would cause harm. That is not a clean bill. It is a blank page where two neighbors have entries — and the two peptides with entries are CJC-1295 and ipamorelin, both of which have been through a trial. BPC-157 has not, so there was nowhere for an event to be recorded in the first place.
What the 2026 reviews concluded
Two reviews published this year cover the same menu these telehealth companies sell. A narrative review in Sports Medicine walks through AOD-9604, BPC-157, CJC-1295, GHK-Cu, ipamorelin, MOTS-c, sermorelin, tesamorelin and thymosin beta-4 together, and concludes that many of the unapproved ones show favorable tissue repair in animals while human safety data are scarce and the potential for serious harm is real[6]. A structured review in JBJS Reviews, covering human and translational evidence from 2020 through August 2025, puts BPC-157 and the thymosin derivatives in the same bucket as the growth-hormone secretagogues: investigational, with uncertain safety profiles and product quality concerns[7].
Both reviews raise product quality as a safety issue in its own right, separate from the molecule. That is the argument we take apart in what third-party testing actually proves, and it is the part of the risk a reader can do something about.
Who sells it, and what to ask them
Seven priced lines across the sellers we review are BPC-157, from five sellers: Live Vital, Blis MD, YOURx Health, ElitePhysiqMD, and Pepti. For scale, the same kind of pattern finds sermorelin on 46 of the 387 sellers we have read, so a small count here is a small count, not a broken search.
- Which pharmacy compounds it, and whether that pharmacy is a state-licensed 503A or an FDA-registered outsourcing facility. Only the second is subject to current good manufacturing practice requirements[8].
- What the vial's beyond-use date is, and what it is based on.
- What the seller will do if you have a reaction — who you call, and whether they report it to the FDA.
- What the month-two price is, once any introductory rate ends. That one has nothing to do with safety and everything to do with what you will actually pay; our price method explains how we read it.
Questions people actually ask
What are the known side effects of BPC-157?
The two-person intravenous pilot assessed short-term safety without a placebo group. It cannot establish how often side effects occur or assess uncommon or long-term harms.
Is BPC-157 considered safe?
The FDA's published position is that it has identified no or only limited safety information for the proposed routes of administration, and therefore lacks enough information to know whether the drug would cause harm in humans. That is a statement about the evidence, not a verdict about the molecule.
Why does the FDA name harms for other peptides but not this one?
Because harms get recorded where somebody was watching. CJC-1295 and ipamorelin were each given to people in a trial, so there were investigators collecting adverse events. BPC-157 has never been through one, so there is no file for an event to land in.
Does a compounded BPC-157 vial carry its own risks?
Yes, and they are separate from the molecule. The FDA's stated concerns about compounded peptides are immunogenicity, peptide-related impurities and characterizing the active ingredient at all. Those are manufacturing risks, and they apply to the vial in front of you rather than to the peptide in the abstract.
Sources
Primary sources and the claims they support.
- 1.Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine, 2025. PMID 40131143An uncontrolled intravenous safety pilot in two adults with short follow-up; it cannot establish general safety or a placebo-comparative adverse-event rate.
- 2.FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. U.S. Food and Drug Administration, 2026. Source · Document dated July 2026The committee was asked whether BPC-157, KPV, TB-500 and MOTS-c (July 23) and emideltide, epitalon and Semax (July 24) should be added to the 503A bulks list. For each one, in both the free-base and acetate forms, the FDA's own proposal was that it NOT be included. The document says the FDA will not issue a final determination until the committee's input has been considered.
- 3.FDA Panel Backs 6 Peptides for Compounding. AJMC (trade press report of the committee vote), 2026. SourceTrade press, not an FDA document: the committee voted 8-6 with 1 abstention to recommend BPC-157, KPV and TB-500, 7-5 with 2 abstentions for MOTS-c, also recommended epitalon and Semax, and voted emideltide down 7-6 with 1 abstention.
- 4.PubMed, queried through the E-utilities API. National Library of Medicine, 2026. SourceOn September 11, 2026, "BPC 157" returned 228 records; with the animal indexing tag, 162; with the human indexing tag, 53; with safety, adverse, toxicity or tolerability terms, 49, falling to 20 when the human tag is added; with MeSH adverse-effects or toxicity subheadings, 36.
- 5.Substances in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026On the page whose own face date reads April 22, 2026, the FDA records specific serious adverse events for CJC-1295 (increased heart rate and systemic vasodilatory reaction) and for ipamorelin acetate (including death), while for BPC-157 it records that it has identified no, or only limited, safety-related information and therefore lacks sufficient information to know whether the drug would cause harm.
- 6.Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine, 2026. PMID 41966639 · doi:10.1007/s40279-026-02437-0A 2026 narrative review covering AOD-9604, BPC-157, CJC-1295, GHK-Cu, ipamorelin, MOTS-c, sermorelin, tesamorelin, thymosin beta-4 and TB-500 concludes that many unapproved peptides show favorable tissue repair and metabolic outcomes in animal models while rigorous human safety data are scarce and there is potential for serious harm.
- 7.Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Reviews, 2026. PMID 42160466 · doi:10.2106/JBJS.RVW.26.00027A structured narrative review of human and translational evidence from January 2020 to August 2025 places regenerative peptides such as BPC-157 and thymosin derivatives, and growth hormone axis secretagogues such as CJC-1295, ipamorelin and tesamorelin, as investigational, with uncertain safety profiles and product quality concerns.
- 8.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025Drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements; drugs compounded by a licensed pharmacist in a state-licensed pharmacy under section 503A are not.
Key figures